# Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

> **NCT06180278** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 32 (actual)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **OTHER:** Blood tests
- **DRUG:** Inebilizumab

## Key facts

- **NCT ID:** NCT06180278
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-02
- **Primary completion:** 2028-06-26
- **Final completion:** 2028-06-26
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06180278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06180278, "Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06180278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*